AMRXMEDIUM SIGNALOPERATIONAL10-K

AMRX replaced its Metsera obesity/metabolic disease collaboration with a 15-year strategic manufacturing partnership with ApiJect Systems for advanced drug delivery at its Brookhaven facility.

The pivot from a development-focused partnership in weight management to a manufacturing services agreement with ApiJect represents a meaningful shift in strategic direction toward contract manufacturing capabilities. This change, combined with substantially higher operating income, suggests AMRX is repositioning itself to capture more value from manufacturing operations rather than pursuing collaborative drug development in competitive therapeutic areas.

Comparing 2026-02-27 vs 2025-02-28View on EDGAR →
FINANCIAL ANALYSIS

AMRX delivered a strong operational performance with substantially higher operating income while maintaining disciplined expense growth, as SG&A expenses rose only modestly. The balance sheet strengthened meaningfully with current assets growing 20% while current liabilities declined 22%, and the company reduced its stockholders' equity deficit by over one-third. Operating cash flow grew solidly at 15%, supporting increased capital expenditures that likely reflect investments in the new ApiJect manufacturing partnership.

FINANCIAL STATEMENT CHANGES
Operating Income
P&L
+58.1%
$249.3M→$394.1M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Stockholders Equity
Balance Sheet
+35.2%
-$109.3M→-$70.8M

Equity base grew 35.2% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Capital Expenditure
Cash Flow
+34.9%
$51.9M→$70.1M

Capital expenditure jumped 34.9% — major investment cycle underway; assess returns on deployment.

Current Liabilities
Balance Sheet
-22%
$1.1B→$881.6M

Current liabilities reduced — improved short-term financial position and working capital health.

Current Assets
Balance Sheet
+20.4%
$1.6B→$1.9B

Current assets grew 20.4% — improving short-term liquidity or inventory/receivables build.

Operating Cash Flow
Cash Flow
+15.2%
$295.1M→$340.0M

Operating cash flow grew 15.2% — strong conversion of earnings to cash, healthy business fundamentals.

Accounts Receivable
Balance Sheet
+12%
$662.6M→$741.8M

Receivables grew 12% — monitor days sales outstanding for collection efficiency.

SG&A Expense
P&L
+10.6%
$476.4M→$526.8M

SG&A increased modestly — likely reflects growth-related hiring or sales expansion investment.

LANGUAGE CHANGES
NEW — 2026-02-27
PRIOR — 2025-02-28
ADDED
As of February 13, 2026, there were 314,629,101 shares of the registrant s Class A common stock outstanding, with a par value of $0.01.
Refer to the section Segments of the Business below for an overview of our segments.
Nature of Operations for additional information about the Reorganization.
Alliance and Collaboration ApiJect Systems Collaboration Agreement On May 8, 2025, we entered into a 15-year strategic collaboration agreement with ApiJect Systems, Corp.
and related entities ( ApiJect ), a medical technology company focused on advanced drug delivery ( ApiJect Agreement ).
Under the ApiJect Agreement, we will install and operate manufacturing equipment leased from Apiject at our Brookhaven, New York facility.
This equipment will be used to support production of ApiJect s proprietary blow fill seal ( BFS ) delivery systems and our growing injectable portfolio.
We will pay a low-digit royalty to ApiJect for any of our commercial products that are manufactured utilizing the equipment.
At the conclusion of the term of the ApiJect Agreement, we have the right to purchase the equipment from ApiJect for a nominal amount.
We will also collaborate with ApiJect on the development of additional injectable product programs utilizing ApiJect s BFS platform.
REMOVED
As of February 14, 2025, there were 309,966,341 shares of the registrant s Class A common stock outstanding, with a par value of $0.01.
Refer to the section Segments of the Business below for an overview of our segments, including the change in name of the Affordable Medicines segment.
Nature of Operations in our consolidated financial statements for additional information about the Reorganization.
Alliance and Collaboration Collaboration to Develop and Supply Medicines for Obesity and Metabolic Diseases On September 30, 2024, we entered into a collaboration agreement to develop and supply a new portfolio of weight loss medicines globally with Metsera, Inc.
( Metsera ), a clinical stage biopharmaceutical company (the Metsera Agreement ).
We will serve as Metsera s preferred supply partner for developed markets, including the United States and Europe.
In addition, we have been granted an exclusive license to commercialize Metsera products covered under the agreement in selected emerging markets, including India and certain countries in Southeast Asia, Africa and the Middle East.
Under the terms of the Metsera Agreement, we will be responsible for performing certain development activities on behalf of Metsera.
Upon Metsera obtaining regulatory approval for any or all the weight loss medicines referred to above, we will manufacture commercial products on behalf of Metsera.
We plan to construct two new greenfield manufacturing facilities in India; one for peptide synthesis and one for sterile fill-finish manufacturing.
MORE OPERATIONAL SIGNALS
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NOWHIGHServiceNow has fundamentally repositioned itself as an AI-first platform company...
2026-01-29
TSLAHIGHTesla has fundamentally repositioned itself from an electric vehicle company to ...
2026-01-29
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →